Novo Nordisk has announced significant price reductions for its obesity treatments, Wegovy and Ozempic, in an effort to compete more effectively against rival Eli Lilly, which...
Shares in Novo Nordisk dropped by as much as 3 percent on Friday following a pricing agreement between the Danish pharmaceutical company and its U.S. competitor...
